Wakisaka N, Moriyama-Kita M, Kondo S, Kobayashi E, Ueno T, Nakanishi Y
PLoS One. 2025; 20(1):e0316102.
PMID: 39820810
PMC: 11737673.
DOI: 10.1371/journal.pone.0316102.
Fritsch N, Aparicio-Soto M, Curato C, Riedel F, Thierse H, Luch A
Toxics. 2024; 12(11).
PMID: 39590982
PMC: 11598016.
DOI: 10.3390/toxics12110802.
Vredevoogd D, Apriamashvili G, Levy P, Sinha S, Huinen Z, Visser N
J Immunother Cancer. 2024; 12(11).
PMID: 39510795
PMC: 11552591.
DOI: 10.1136/jitc-2024-010145.
Khan M, Huang X, Ye X, Zhang D, Wang B, Xu A
Ann Med. 2024; 56(1):2405079.
PMID: 39387496
PMC: 11469424.
DOI: 10.1080/07853890.2024.2405079.
Fang M, Allen A, Luo C, Finn J
Front Immunol. 2024; 15:1457629.
PMID: 39281684
PMC: 11392856.
DOI: 10.3389/fimmu.2024.1457629.
Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.
Li J, Zhou W, Wang W
Cell Mol Life Sci. 2024; 81(1):378.
PMID: 39215816
PMC: 11365909.
DOI: 10.1007/s00018-024-05412-y.
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
Imianowski C, Kuo P, Whiteside S, von Linde T, Wesolowski A, Conti A
Cancer Res Commun. 2024; 4(8):2045-2057.
PMID: 38995700
PMC: 11317917.
DOI: 10.1158/2767-9764.CRC-23-0500.
GITR exacerbates lysophosphatidylcholine-induced macrophage pyroptosis in sepsis via posttranslational regulation of NLRP3.
Liang S, Zhou J, Cao C, Liu Y, Ming S, Liu X
Cell Mol Immunol. 2024; 21(7):674-688.
PMID: 38740925
PMC: 11214634.
DOI: 10.1038/s41423-024-01170-w.
Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.
Al-Danakh A, Safi M, Jian Y, Yang L, Zhu X, Chen Q
Front Immunol. 2024; 15:1348189.
PMID: 38590525
PMC: 11000233.
DOI: 10.3389/fimmu.2024.1348189.
CD8 T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs.
Palmeri J, Lax B, Peters J, Duhamel L, Stinson J, Santollani L
Nat Commun. 2024; 15(1):1900.
PMID: 38429261
PMC: 10907589.
DOI: 10.1038/s41467-024-45625-0.
Assessing the functional potential of conditioned media derived from amniotic epithelial stem cells engineered on 3D biomimetic scaffolds: An in vitro model for tendon regeneration.
Russo V, Prencipe G, Mauro A, El Khatib M, Haidar-Montes A, Cambise N
Mater Today Bio. 2024; 25:101001.
PMID: 38420144
PMC: 10899023.
DOI: 10.1016/j.mtbio.2024.101001.
Tregs from human blood differentiate into nonlymphoid tissue-resident effector cells upon TNFR2 costimulation.
Mensink M, Verleng L, Schrama E, Janssen G, Tjokrodirijo R, Van Veelen P
JCI Insight. 2024; 9(5).
PMID: 38341270
PMC: 10972588.
DOI: 10.1172/jci.insight.172942.
Dendritic Cell-Based Immunity: Screening of Dendritic Cell Subsets in Breast Cancer-Bearing Mice.
Aldahlawi A, Zaher K
J Microsc Ultrastruct. 2023; 11(3):150-160.
PMID: 38025181
PMC: 10679829.
DOI: 10.4103/jmau.jmau_85_22.
T Cell Response in Tuberculosis-Infected Patients Vaccinated against COVID-19.
Cavalcante-Silva L, Leite E, Almeida F, de Andrade A, Comberlang F, Lucena C
Microorganisms. 2023; 11(11).
PMID: 38004820
PMC: 10673403.
DOI: 10.3390/microorganisms11112810.
CD137L Inhibition Ameliorates Hippocampal Neuroinflammation and Behavioral Deficits in a Mouse Model of Sepsis-Associated Encephalopathy.
Qiu F, Liu Y, Liu Y, Zhao Z, Zhou L, Chen P
Neuromolecular Med. 2023; 25(4):616-631.
PMID: 37796401
PMC: 10721669.
DOI: 10.1007/s12017-023-08764-z.
Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.
Cortellino S, Quagliariello V, Delfanti G, Blazevits O, Chiodoni C, Maurea N
Nat Commun. 2023; 14(1):5529.
PMID: 37684243
PMC: 10491752.
DOI: 10.1038/s41467-023-41066-3.
Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Redmond W
Expert Opin Biol Ther. 2023; 23(9):901-912.
PMID: 37587644
PMC: 10530613.
DOI: 10.1080/14712598.2023.2249396.
BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy.
Liang S, Zheng D, Liu X, Mei X, Zhou C, Xiao C
Front Oncol. 2023; 13:1211759.
PMID: 37576888
PMC: 10421724.
DOI: 10.3389/fonc.2023.1211759.
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z, Luo F, Chu Y
Front Immunol. 2023; 14:1199145.
PMID: 37554322
PMC: 10405079.
DOI: 10.3389/fimmu.2023.1199145.
Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.
Bolivar A, Duzagac F, Sinha K, Vilar E
Mol Aspects Med. 2023; 93:101204.
PMID: 37478804
PMC: 10528439.
DOI: 10.1016/j.mam.2023.101204.